However, sometimes epilepsy medication can cause harm to the patient or even their unborn child. This is particularly the case with Sodium Valproate, which goes by the brand names Epilim and Depakote.
Next week, women whose children have been harmed by this drug will give evidence to a European-wide safety review that will examine whether warnings about risks to unborn babies are strong enough.
All medication – not just Sodium Valproate – of course, has side-effects and risks. These must be weighed up against the benefits of medication. In order to weigh up the pros and cons, the patient and treating team must know what the risks and side-effects could be. Worryingly, this has not always been the case with Epilim – and I can say that from personal experience when I took the drug some years ago.
Sodium Valproate/Epilim used to be a very common medication for people with epilepsy, but for many years it has been known that Epilim increases the risk of a baby born to a mother taking Epilim suffering physical abnormalities and cognitive impairments. Babies exposed to Epilim/Sodium Valproate in the womb have a 10% chance of developing physical abnormalities and a 4 in 10 chance of developing cognitive problems, such as learning disabilities and autism. Evidence of this risk emerged back in the 1980s, but for years many patients have not been told about the risk. Medical advice now is that Epilim/Sodium Valproate should not be used during pregnancy unless there is no safer alternative and only after a careful discussion of the risks.
There is currently a group action in France against the drug company which makes Sodium Valproate, Sanofi. In the past, there was also a group action in the UK.
Whilst drug companies must give comprehensive and clear advice on all side-effects and potential risks, the responsibility to inform a patient and weigh up the pros and cons does not fall solely to the drug company. A patient's treating doctor must advise the patient about the side-effects and risks. The doctor might have been negligent if she fails to do so.
Doctors are under a duty to take reasonable care to ensure that the patient is aware of any material risks involved in any recommended treatment and of any reasonable alternative or variant treatments. A significant risk is one which would affect the judgment of a reasonable patient. Surely a 10% risk of a baby developing physical abnormalities and a 25% risk of cognitive problems is a significant risk that doctors should make all patients aware of so that they can make their own decision about their life and that of future children.
Ann Houghton is an associate in our clinical negligence team and is responding to an article on the BBC website today.
On 8 December 2021, the Competition and Markets Authority (the CMA) published its revised consumer law advice for care home providers (Guidance).
As solicitors, we see and hear first-hand the issues that most often cause difficulties and have compiled our own ’10 top tips on how to stay together at Christmas’.
In this podcast, Jon Coane looks at the benefits of making loans and the issues that local authorities need to be aware of.
The Government has released several factsheets on the Building Safety Bill. We will be reviewing these and outlining how they can assist providers to prepare for the new building safety regime.
With the new law, spouses will be able to achieve a good divorce, making the best of a bad situation.
Anthony Collins Solicitors is able to be at the forefront of family law issues and to be a driving force for change and promotion of conciliatory working.
Anthony Collins Solicitors is supporting Resolution’s Good Divorce Week commencing on 29 November. But what is Resolution, what’s its purpose and what is a Good Divorce Week?
Anthony Collins Solicitors (ACS) has been named Family Law Firm of the Year: Midlands and Wales at the prestigious Family Law Firm Awards.
A social care provider (Be Caring Limited) was facing a charge of £180,000 plus VAT to cancel 800 mobile phone connections.
Puja Desai interviews employees around the firm and discusses their experience with different invisible illnesses. The first part was on diabetes, the second MS and this podcast focuses on epilepsy.
To receive invitations to our events, as well as information and articles on legal issues and sector developments that are of interest to you, please sign up to Newsroom.